Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1152 Results

Title
Intervention Indication Therapeutic Area Year Actions
Baricitinib for systemic lupus erythematosus Baricitinib (LY3009104; Olumiant) Systemic lupus erythematosus (SLE) Immunology , Nephrology 2021 View  |  Download
Baricitinib for moderate to severe atopic dermatitis Baricitinib (LY3009104; Olumiant) , Corticosteroids Atopic dermatitis Dermatology 2019 View  |  Download
Bardoxolone Methyl for the treatment of chronic kidney disease (CKD) caused by Alport Syndrome Bardoxolone Methyl Alport Syndrome , Chronic kidney disease (CKD) Genetic Disorders , Nephrology 2022 View  |  Download
Baloxavir marboxil for treatment of influenza A or B infection in otherwise healthy patients aged 12 years and older Baloxavir marboxil (Xofluza; S-033188) Influenza Infectious Disease 2018 View  |  Download
Baloxavir marboxil for treating paediatric patients 1 to <12 years of age with influenza Baloxavir marboxil (Xofluza; S-033188) Influenza Infectious Disease 2021 View  |  Download
Baloxavir marboxil for the treatment of influenza in patients aged 12 years and older and are at high risk of developing influenza complications Baloxavir marboxil (Xofluza; S-033188) Influenza Infectious Disease 2020 View  |  Download
Baloxavir marboxil for the post-exposure prevention of influenza in people aged 12 years and older Baloxavir marboxil (Xofluza; S-033188) Influenza Infectious Disease 2020 View  |  Download
AZD3152 for preventing COVID-19 AZD3152 COVID-19 Infectious Disease 2023 View  |  Download
Axitinib for Patients at High Risk of Recurrence of Renal Cell Carcinoma – Adjuvant Axitinib (Inlyta; AG-013736) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) – second line Brexucabtagene autoleucel (Tecartus; KTE-X19) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications